Axsome Therapeutics vs Zhejiang Huahai Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Axsome Therapeutics Inc (AXSM)

Q3 202610 Aug – 25 Sep 2026

▲4

Axsome's Alzheimer's Launch Drives Record Prescriptions, Pipeline Advances

Record Auvelity Prescriptions on Alzheimer's Launch Auvelity prescriptions hit a record ~23,500 weekly, with new-to-brand scripts reaching 3,800 as the Alzheimer's agitation launch grows. Patients 65+ now make up 31% of new scripts, up from 19%, showing strong demand and supporting the $8 billion peak-sales outlook.
This is the core demand driver behind the stock's recent move and the biggest new commercial catalyst.
Pipeline Advances with AXS-12 PDUFA and Phase III Start AXS-12 for cataplexy got a May 1, 2027 PDUFA date, and Axsome dosed the first patient in a Phase III study of AXS-05 for smoking cessation. Management targets roughly one new drug filing per year through 2030, expanding the pipeline beyond current products.
Shows new growth opportunities beyond Auvelity, which supports the long-term investment case.
Strong Q2 Revenue and Path to Cash Flow Positive Q2 net product revenue rose 46% to $218 million, led by Auvelity and Sunosi. Management expects revenue to grow faster than expenses, with $320 million cash funding operations into cash flow positivity, reducing financing risk.
Financial strength and profitability path are key to sustaining investor confidence.
Analyst Backing and New Clinical Data B. Riley named Axsome a top biotech pick with a $300 price target ahead of Q3 earnings. New clinical data in depression and Alzheimer's agitation were presented, adding detail to the pipeline and supporting future regulatory interactions.
Analyst endorsement and data reinforce the growth narrative and can attract investors.

September 202610 Aug – 25 Sep 2026

▲4

Axsome's Alzheimer's Launch Drives Record Prescriptions, Pipeline Advances

Record Auvelity Prescriptions on Alzheimer's Launch Auvelity prescriptions hit a record ~23,500 weekly, with new-to-brand scripts reaching 3,800 as the Alzheimer's agitation launch grows. Patients 65+ now make up 31% of new scripts, up from 19%, showing strong demand and supporting the $8 billion peak-sales outlook.
This is the core demand driver behind the stock's recent move and the biggest new commercial catalyst.
Pipeline Advances with AXS-12 PDUFA and Phase III Start AXS-12 for cataplexy got a May 1, 2027 PDUFA date, and Axsome dosed the first patient in a Phase III study of AXS-05 for smoking cessation. Management targets roughly one new drug filing per year through 2030, expanding the pipeline beyond current products.
Shows new growth opportunities beyond Auvelity, which supports the long-term investment case.
Strong Q2 Revenue and Path to Cash Flow Positive Q2 net product revenue rose 46% to $218 million, led by Auvelity and Sunosi. Management expects revenue to grow faster than expenses, with $320 million cash funding operations into cash flow positivity, reducing financing risk.
Financial strength and profitability path are key to sustaining investor confidence.
Analyst Backing and New Clinical Data B. Riley named Axsome a top biotech pick with a $300 price target ahead of Q3 earnings. New clinical data in depression and Alzheimer's agitation were presented, adding detail to the pipeline and supporting future regulatory interactions.
Analyst endorsement and data reinforce the growth narrative and can attract investors.

Latest10 Aug – 25 Sep 2026

▲4

Axsome's Alzheimer's Launch Drives Record Prescriptions, Pipeline Advances

Record Auvelity Prescriptions on Alzheimer's Launch Auvelity prescriptions hit a record ~23,500 weekly, with new-to-brand scripts reaching 3,800 as the Alzheimer's agitation launch grows. Patients 65+ now make up 31% of new scripts, up from 19%, showing strong demand and supporting the $8 billion peak-sales outlook.
This is the core demand driver behind the stock's recent move and the biggest new commercial catalyst.
Pipeline Advances with AXS-12 PDUFA and Phase III Start AXS-12 for cataplexy got a May 1, 2027 PDUFA date, and Axsome dosed the first patient in a Phase III study of AXS-05 for smoking cessation. Management targets roughly one new drug filing per year through 2030, expanding the pipeline beyond current products.
Shows new growth opportunities beyond Auvelity, which supports the long-term investment case.
Strong Q2 Revenue and Path to Cash Flow Positive Q2 net product revenue rose 46% to $218 million, led by Auvelity and Sunosi. Management expects revenue to grow faster than expenses, with $320 million cash funding operations into cash flow positivity, reducing financing risk.
Financial strength and profitability path are key to sustaining investor confidence.
Analyst Backing and New Clinical Data B. Riley named Axsome a top biotech pick with a $300 price target ahead of Q3 earnings. New clinical data in depression and Alzheimer's agitation were presented, adding detail to the pipeline and supporting future regulatory interactions.
Analyst endorsement and data reinforce the growth narrative and can attract investors.

Zhejiang Huahai Pharmaceutical Co Ltd (600521.CG)

Q3 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

August 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

Latest24 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.